Issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 7, 1998, Pages 591-603

  Friend, D R ^a,b  

^a CIBUS Pharmaceutical Inc   (United States)

^b CIBUS Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETAMETHASONE; BUDESONIDE; CORTICOSTEROID; CORTISONE; CORTISONE ACETATE; DESONIDE; DESOXIMETASONE; DEXAMETHASONE; FLUDROCORTISONE; FLUNISOLIDE; FLUOCORTOLONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISOLONE 21 PHOSPHATE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISONE; TIXOCORTOL PIVALATE; TRIAMCINOLONE ACETONIDE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID;

COLITIS; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TARGETING; ENTERITIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTESTINE FLORA; INTESTINE TRANSIT TIME; ORAL DRUG ADMINISTRATION; PH; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS; AREA UNDER THE CURVE; DRUG EFFECT; HALF LIFE TIME; STOMACH EMPTYING;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; BUDESONIDE; GASTRIC EMPTYING; GLUCOCORTICOIDS; HALF-LIFE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 0032113179     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00348.x     Document Type: Review

References (120)

1. Rubinstein A. Approaches and opportunities in colon-spenlic drug delivery. Crit Rev Ther Drug Currier Syst 1995; 12: 101-49.
2. Wilding IR, Davis SS, O'Hagan DT. Targeting of drugs and vaccines to the gut. Pharmacol Ther 1994; 62: 97-124.
3. Friend DR. Colon-specific drug delivery. Adv Drug Del Rev 1991; 7: 149-99.
4. Rubinstein A, Friend DR. Specific delivery to the gastrointestinal tract. In: Domb AJ. ed. Polymeric Site-Specific Pharmacotherapy. Chichester: John Wiley & Sons Ltd. 1994: 267-313.
5. Watts PJ Illum L. Colonic drug delivery. Drug Devel Ind Pharm 1997; 23: 893-913.
6. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos 1990; 11: 465-75.
7. Both H. Torp-Pedersen K. Kreiner S. et al. Clinical appearance at diagnosis of ulcerative colities and Crohn's disease in a regional patient group. Scand J Gastroenterol 1983; 18: 987-91.
8. Andus T, Targan SR. Glucocorticoids. In: Targan SR. Shanahan F. eds. Inflammatory Bowel Disease. From Bench to Bedside. Baltimore: Williams and Wilkins. 1994: 487-502.
9. Gustafsson J-A. Carlstedt-Duke J. Poellinger L. et al. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev 1987; 8: 185-234.
10. Distelhorst CW. Recent insights into the structure and function of the glucocorticoid receptor. J Lab Clin Med 1989; 113: 404-12.
11. Fauci AS. Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Ann Intern Med 1976; 84: 304-15.
12. Schleimer RP. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Respir Dis 1990; 141 (Suppl.): 50-60.
13. Kuritzkes R. Shanahan F. Corticosteroid therapy. In: Gitnick G. ed. Steroids and Inflammatory Bowel Disease. Tokyo: Igaku-Shoin. 1990: 299-321.
14. MacDermoll RP. Cell-mediated immunity in gastrointestinal disease. Hum Pathol 1986; 17: 219-33.
15. Von Herbay A. Gebbers J-O. Otto HF. Immunopathology of ulcerative colitis: a review, Hepatogastroenterology 1990; 37: 99-107.
16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Preliminary report on a therapeutic trial. Br Med J 1954; 2: 375-8.
17. Lennard-Jones JE. Longmore AJ. Newell AC. et al. An assessment of prednisolone. salazopyrin. and topical hydrocortisone hemisuecutate used as out-patient treatment of ulcerative colitis. Gut 1960; 1: 217-222.
18. Pickup ME. Clinical pharmacokineties of prednisone and prednisolone. Clin Pharmacokinet 1979; 4: 111-28.
19. Swartz S. Dluhy R. Corticosteroids: clinical pharmacology and therapeutic use. Drugs 1978; 16: 238-55.
20. Kusunoki M. Möeslein G. Shoji Y. et al. Steroid complications in patients with ulcerative colitis. Dis Colon Rectum 1992: 35: 1003-9.
21. Lee DAH, Taylor M, James VTH, et al. Rectally administered prednisolone evidence for a predominantly local action. Gut 1980; 21: 215-18.
22. Sandle GI, Hayslett JP, Binder HJ. Effect of glucorticoids on rectal transport in normal subjects and patients with ulcerative colitis. Gut 1986; 27: 309-16.
23. Peña AS. A comparative review of available rectal steroids in the treatment of distal disease. Res Clin Forums 1993; 15: 57-64.
24. Flavell Matts SG, Intrarectal treatment of 100 cases of ulcerative colitis with prednisolone 21-phosphate enemata. Br Med J 1961; 2: 165-8.
25. Powell-Tuck J. Lennard-Jones JE, May CS. et al. Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis. Br Med J 1976; 1:193-5.
26. Halpern Z. Sold O. Baratz M. et al. A controlled trial of beclomethasone versus betamethasone enemas in distal ulcerative colitis. J Clin Gastroenterol 1991; 13: 38-41.
27. Kumana CR, Seaton T. Casteli M. et al. Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary-adrenal suppression. Lancet 1982; 1: 579-83.
28. Bansky G. Buhler H. Stamm B. et al. Treatment of distal ulcerative colitis with beclomethasone enemas: High therapeutic efficacy without endocrine side effects. Dis Colon Rectum 1987; 30: 288-92.
29. McIntyre PB. Macrae FA, Berghouse L. et al. Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis. Gut 1985; 26: 822-4.
30. Truelove SC. Treatment of ulcerative colitis with local hydrocortisone. Br Med J 1956; 2: 1267-72.
31. Matts S. Betamethasone enemata in ulcerative colitis. Gut 1962; 3: 312-14.
32. Spencer J. Kirsner JB. Experience with short and long term courses of local adrenal steroid therapy in ulcerative colitis. Gastroenterology 1962; 6: 669-77.
33. Farmer RG. Schumacher OP. Treatment of ulcerative colitis with hydrocortisone enemas: relationship of hydrocortisone absorption. adrenal suppression and clinical response. Dis Colon Rectum 1970; 13: 355-61.
34. Nyman-Pantelidis N. Nilsson A. Wagner ZG. et al. Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 617-22.
35. Campieri M. Corbelli C. Giochetti P. et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992; 37: 1890-7.
36. Ruddel WSJ. Dickinson RJ. Dixon MF. et al. Treatment of distal ulcerative colitis (proctosidmoiditis) in relapse, comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut 1980; 21: 885-9.
37. Moody GA, Eaden JA, Helyes Z, et al. Oral or rectal administration of drugs in IBD. Aliment Pharmacol Ther 1997; 11: 999-1000.
38. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407-14.
39. Tozer TN. Friend DR. McLeod AD. Kinetic perspectives on colonic delivery. STP Pharma Sciences 1995; 5: 5-12.
40. McLeod AD. Cui N. Friend DR. et al. A novel dextranglucocorticosteroid prodrug accelerates healing with limited adrenal suppression in experimental colitis in rats. Gastroenterology 1994; 106: 405-13.
41. Fedorak RN. Cui N. Friend DR. A budesonide prodrug accelerates treatment of colitis in rats. Gut 1994; 35: 1439-46.
42. Fedorak RN. Haeberlin B. Empey I., et al. Colonic delivery of dexamethasone from a prodrug accelerates healing of experimental colitis without adrenal suppression. Gastroenterology 1995; 108: 1688-99.
43. Larochelle P. DuSouich P, Bolte E. et al. Tixicortole pivalate. a corticosteroid with no systemic glucocorticoid effect after oral. intrarectal. and intranasal application. Clin Pharmacol Ther 1983; 33: 343-50.
44. Edsbacker S, Andersson P, Lindberg C. et al. Liver metabolism of budesonide in rat. mouse. and man. Comparative aspects. Drug Metab Dispos 1985; 15: 403-11.
45. Edsbacker S. Jonsson S. Lindberg C. et al. Metabolic pathways of the topical glucocorticoid budesonide in man. Drug Metab Dispos 1983; 11: 590-6.
46. Ryrfeldt A. Andersson P. Edsbacker S. et al. Pharmacokinetics and metabolism of budesonide. a selective glucocorticoid. Eur J Resp Dis 1982: 63 (Suppl. 122): 86-95.
47. Spencer CM. McTavish D. Budesonide. a review of its pharmacological and therapeutic efficacy in inflammatory bowel disease. Drugs 1995; 50: 854-72.
48. Borgden RN. McTavish D. Budesonide. an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44: 375-407.
49. Clissold SP. Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 485-518.
50. Löfberg R. Danielsson A. Suhr O. et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996; 110: 17135-18.
51. Schreiber S. Schottelius A. Baumann J. et al. Immunopharmacology of budesonide inhibition of pro-inflammatory cytokine secretion by IBD mononuclear phagocytes. Gastroenterology 1996; 112: A1011.
52. Tromm A. Möllmann HW. Schwegler U. et al. Pharmacokinetics and -dynamics of budesonide (BUD) after oral topical administration. Gastroenterology 1995; 104: A792.
53. Tromm A. Möllmann HW. Barth J. et al. Multiple oral application of budesonide (BUD) in sustained release capsules and tablets: Results of a pharmacokinetic and -dynamic study in healthy volunteers. Gastroenterology 1994; 106: A784.
54. Campieri M. Ferguson A. Doe W. Oral budesonide competes favorably with prednisolone in active Crohn's disease. Gastroenterology 1995; 108: A790.
55. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease. Gastroenterology 1995; 108: A827.
56. Bye A. The oral systemic availability of flucticasone propionate in man - preliminary data. Br J Clin Pharmacol 1993; 36: 136-7.
57. Harding SM. The human pharmacology of fluticasone propionate. Resp Med 1990; 84 (Suppl. A): 25-9.
58. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996; 97: 169-76.
59. Carpani de Kaski M. Peters AM. Lavender JP. et al. Fluticasone propionate in Crohn's disease. Gut 1991; 32: 657-61.
60. Hawthorne AB, Record CO. Holdsworth MH, et al. Double blind trial of oral tluticasone versus prednisolone in the treatment of active ulcerative colitis. Gut 1993; 34: 125-8.
61. Angus P, Snook JA, Reid MI, et al. Oral tluticasone propionate in active distal ulcerative colitis. Gut 1993; 33: 711-14.
62. Rohatagi S, Bye A, Falcoz C, et al. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996; 36: 938-41.
63. Steed KP, Hooper G, Ventura P, et al. The in vivo behaviour of a colonic delivery system: a pilot study in man. Int J Pharm 1994; 112: 199-206.
64. Evans DF, Pye G, Bramley R, et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988; 29: 1035-41.
65. McDougal CJ, Wong R, Scudera P, et al. Colonic mucosal pH in humans. Dig Dis Sci 1993; 38: 542-5.
66. Fallingborg J. Christensen LA. Ascanius B. et al. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 1993; 38: 1989-93.
67. Sasaki Y, Hada R, Nakajima H, et al. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: Colonic luminal pH in normal subjects and patients with Crohn's disease. Am J Gastroenterol 1997; 92: 114-18.
68. Ashford M. Fell JT. Attwood D. et al. An in vitro investigation into the suitability of pH-dependent polymers for colon targeting. Int J Pharm 1993; 91: 241-5.
69. Ashford A. Fell AT. Attwood D. et al. An in vivo investigation into the suitability of pH dependent polymers for colonic targeting. Int J Pharm 1993; 95: 193-9.
70. Rubinstein A, Li VHK, Gruber P, et al. Gastrointestinal-physiological variables affecting the performance of oral sustained release dosage forms. In: Yacobi A. Halperin-Walega E, eds. Oral Sustained Release Formulations: Design and Evaluation. New York: Pergamon Press. 1988; 125-56.
71. Coupe AJ, Davis SS, Evans DF, et al. Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility. Pharm Res 1991; 8: 1281-85.
72. Davis SS. Hardy J. Fara JW Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27: 886-92.
73. Fallingborg J. Christensen LA. Ingeman-Nielsen M. et al. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 1989; 5: 605-13.
74. Davis SS. Stockwell MJ. Taylor MJ. et al. The effect of density on gastric emptying of single and multiple unit dosage forms. Pharm Res 1986; 3: 208-13.
75. Khosla R. Feely LC. Davis SS. Gastrointestinal transit of nondisintegrating tablets in fed subjects. Int J Pharm 1989; 53: 107-17.
76. Wilding IR. Hardy JG. Maccari M. et al. Scintigraphic and pharmacokinelic assessment of a multiparticulate sustained release formulation of diltiazem. Int J Pharm 1991; 76: 133-43.
77. Spiller RC, Brown ML, Philips SF, Emptying of the terminal ileum in intact humans. Gastroenterology 1987; 92: 724-9.
78. Adkin DA. Davis SS. Sparrow RA. et al. Colonic transit of different size tablets in healthy subjects. J Controlled Rel 1993; 23: 147-56.
79. Camilleri M. Colemont LJ. Phillips SF. et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989; 257: G284-90.
80. Krevsky B. Malmud LS. F. D'Ercole F. et al. Colonic transit scintigraphy. A physiologic approach to the quantitative measurement of colonic transit in humans. Gastroenterologv 1986; 91: 1102-12.
81. Proano M. Camilleri M. Phillips SF. et al. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol 1990; 258: G856-62.
82. Davis SS, Hardy JG, Taylor MJ. et al. The in vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol 1984; 36: 740-2.
83. Davis SS. Hardy JG, Taylor MJ. et al. A comparative study of the gastrointestinal transit of a pellet and tablet formulalion. Int J Pharm 1984; 21: 167-77.
84. Hardy JG. Wilson CA. Wood E. Drug delivery to the proximal colon. J Pharm Pharmacol 1985; 37: 874-8.
85. Ahren P. Devroede G, Jehannin B. et al. Segmental colonic transit time. Dis Colon Rectum 1981; 24: 625-9.
86. Hardy JG. Wood E, Wilson CG. The intestinal transit of capsules and pellets. Dig Dis Sci 1985; 30: 772.
87. Eastwood MA. Medical and dietary management. Clinics Gastroenterol 1975; 4: 85-97.
88. Sandborn WJ. Philips SF. Pathophysiology of symptoms and clinical features of inflammatory bowel disease. In: Kirshner JB. Shorter RG. eds. Inflammatory Bowel Disease (4th edn). Baltimore: Williams and Wilkens, 1995; 407-36.
89. Duthie HL. Watts JM. Dedombal FT. et al. Serum electrolytes and colonic transfer of water and electrolytes in chronic ulcerative colitis. Gastroenterology 1964; 47: 525.
90. Rao SSC. Read MW. Brown C, et al. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology 1987; 93: 934-40.
91. Martelli H. Devroede G. Arhan P. et al. Some parameters of large bowel motility in normal man. Gastroenterology 1978; 75: 612-18.
92. Davis SS. Robertson C. Wilding IR. Gastrointestinal transit of a multiparticulate tablet formulation in patients with active ulcerative colitis. Int J Pharm 1991; 68: 199-204.
93. Rao SSC, Holdsworth CD. Read NW. Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988; 29: 342-5.
94. Lennard-Jones JE. Langmanm MJS. Avery Jones F. Faecal stasis in proctocolitis. Gut 1962; 3: 301-5.
95. Giaffer MH, Holdsworth CD. Duerden BI. The assessment of faecal flora with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 1991; 35: 238-43.
96. Onderdonk AB. Role of intestinal microflora in ulcerative colitis. In: Henteges DJ. ed. Human Intestinal Microflora in Health and Disease. New York: Academic Press, 1983: 481-93.
97. Gillian Hartley, Hudson MJ. Swarbrick ET. et al. The rectal mucosa-associated microflora in patients with ulcerative colitis. J Med Microbiol 1992; 36: 96-103.
98. Gibson GR, Cummings JH, Macfarlane GT. Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol Ecol 1991; 86: 103-12.
99. Benno P. Leijonmarck C-E. Monsen U. et al. Functional alterations of the microflora in patients with ulcerative colitis. Scand J Gastroenterol 1993; 28: 839-44.
100. Wensinck F. Custers-van Lieshout LMC, Poppelaars-Kurstermans PAJ. et al. The faecal flora of patients with Crohn's disease. J Hyg 1981; 87: 1-12.
101. Cooke EM. A quantitative comparison of the faecal Ilora of patients with ulcerative colitis and that of normal persons. J Path Bact 1967; 9: 439-44.
102. Gorbach SL. Nahas L. Plaut AG, et al. Studies of intestinal microllora V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy. Gastroenterology 1968; 54: 575-87.
103. Ruseler-van Embden JGH, Both-Patoir HC. Anaerobic Gram-negative faecal flora in patients with Crohn's disease and healthy subjects. Ant Leeuwen 1983; 49: 125-32.
104. Van der Wiel-Korstanje JAA. Winkler KC. The faecal flora in ulcerative colitis. J Med Microbiol 1974; 8: 491-501.
105. Keighley MRB. Arabi Y. Dimock F. et al. Influence of inflammatory bowel disease on intestinal microflora. Gut 1978; 19: 1099-104.
106. Ruseler-van Embden JGH. Van Lieshout LMC. Increased fecal glycosidases on patients with Crohn's disease. Digestion 1987; 37: 43-50.
107. El Yamni J. Mizon C. Capon C. et al. Decreased fecal exoglycosidase activities identify a subset of patients with active Crohn's disease. Clin Sci 1992; 83: 409-15.
108. Canva-Delcambre V. Soenen V. Mizon A. et al. L'activite beta-galactosidascique fecale est diminuce as cours de la maladie de Crohn. Gastroenterol Clin Biol 1993; 17: 718-22.
109. Rhodes JM. Gallimore R. Elias E. et al. Faecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease. Gut 1985; 26: 761-5.
110. Carrette O, Favier C, Mizon C. et al. Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci 1995; 40: 2641-46.
111. Katori N. Aoyagi N. Terao T. Estimation of agitation intensity in the G1 tract in humans and dogs based on in vitro/in vivo correlation. Pharm Res 1995; 12: 237-43.
112. Shameen M. Katori N. Aoyagi N. et al. Oral solid controlled release dosage forms role of G1-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions in humans. Pharm Res 1995; 12: 1049-54.
113. Macheras P. Argyrakis P. Gastrointestinal drug absorption: Is it time to consider herterogeniety as well as homogeniety. Pharm Res 1997; 14: 842-7.
114. Nittmann J. Daccord G. Stanley HE. Fractal growth of viscous fingers: quantitative characterization of fluid instability phenomenon. Nature 1985; 314: 141-4.
115. Van Damme H. Flow and interfacial instabilities in Newtonian and colloidal fluids (or the birth, life, and death of a fractal). In: Avnir D. ed. The Fractal Approach to Heterogeneous Chemistry. Chichester: John Wiley. 1989: 199-226.
116. Edsbacker S. Johansson SA. Correlation between kinetic properties and clinical safety of budesonide enema (abstract no. PD 561). World Congress Gastroenterology. Syndey, Australia. 1990.
117. Dahlstrom K. Edsbacker S, Conradson T-B. Rectal and oral bioavailability of budesonide in man [abstract no. 297]. Hell J Gastroenterol 1992; 5 (Suppl.).
118. Danielsson A, Edsbacker S. Lofberg R. et al. Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis. Alimment Pharmacol Ther 1993; 7: 401-7.
119. Nilsson M. Edsbacker S, Larsson P. et al. Dose-porportional kinetics of budesonide controlled ileal release capsules [abstract]. Gastroenterology 1995; 108: A885.
120. Sjodahl R. Jansen J. Nilsson M. et al. Pharmacokinetics of budesonide CIR capsules in patients after single dose and after repeated administration of 4.5 mg twice daily. Astra Draco AB: Lund. Sweden. 1995: report no. 08-CR-3016 (data on file).